Gene mutation analysis and quantitation of DNA topoisomerase I in previously untreated non-small cell lung carcinomas

Japanese Journal of Cancer Research

Volumn 88, Issue 2, 1997, Pages 160-165

  Takatani, Hiroshi ^a   Oka, Mikio ^a   Fukuda, Minoru ^a   Narasaki, Fumihiko ^a   Nakano, Reiji ^a   Ikeda, Koki ^a   Terashi, Kenji ^a   Kinoshita, Akitoshi ^a   Soda, Hiroshi ^a   Kanda, Tetsuro ^a   Schneider, Erasmus ^b   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b WADSWORTH CENTER   (United States)

Author keywords

Camptothecin; Drug resistance; Gene mutation; Lung cancer; Topoisomerase I

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; LUNG NON SMALL CELL CANCER; MALE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0030891717     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1997.tb00361.x     Document Type: Article

References (31)

1. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58, 351-375 (1989).
2. Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C. and Kaufmann, S. H. The current status of camptothecin anologues as antitumor agents. J. Natl Cancer Inst., 85, 271-291 (1993).
3. Guputa, M., Fujimori, A. and Pommier, Y. Eukaryotic DNA topoisomerase I. Biochim. Biophys. Acta, 1262, 1-14 (1995).
4. Giovanella, B. C., Steblin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R. and Potmesil, M. DNA topoisomerase I-targeting chemotherapy of human colon cancer in xenografts. Science, 246, 1046-1048 (1989).
5. Takano, H., Kohno, K., Matsuo, K., Matsuda, T. and Kuwano, M. DNA topoisomerase-targeting antitumor agents and drug resistance. Anti-Cancer Drugs, 3, 323-330 (1992).
6. Fukuoka, M., Niitani, H., Suzuki, A., Motomiya, M., Hasegawa, K., Nishiwaki, Y., Kuriyama, T., Ariyoshi, Y., Negoro, S., Masuda, N., Nakashima, S. and Taguchi, T. A phase II study of CPT-11, a new derivative of camptothe- cin, for previously untreated non-small cell lung cancer. J. Clin. Oncol., 10, 16-20 (1992).
7. Masuda, N., Fukuoka, M., Kusunoki, Y., Matsui, K., Takifuji, N., Kudoh, S., Negoro, S., Nishioka, M., Nakagawa, K. and Takada, M. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol., 10, 1225-1229 (1992).
8. Tsuda, H., Takatsuki, K., Ono, R., Masaoka, T., Okada, K., Shirakawa, S., Ohashi, Y., Ota, K. and the CPT-11 study group on hematological malignancy, Tokyo, Japan Treatment of adult T-cell leukemia-lymphoma with ir- inotecan hydrochloride (CPT-11). Br. J. Cancer, 70, 771- 774 (1994).
9. Fukuoka, M. and Masuda, N. Clinical studies of ir- inotecan alone and in combination with cisplatin. Cancer Chemother. Pharmacol., 34, S105-S111 (1994).
10. Wagener, D. J. T., Verdonk, H. E. R., Dirix, L. Y., Catimel, G., Siegenthaler, P., Buitenhuis, M., Mathieu-Bouë, A. and Verweij, J. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Anal. Oncol., 6, 129-132 (1995).
11. Conti, J. A., Kemeny, N. E., Saltz, L. B., Huang, Y., Tong, W. P., Chou, T., Sun, M., Pulliam, S. and Gonzalez, C. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J. Clin. Oncol., 14, 709-715 (1996).
12. Chen, A. Y. and Liu, A. F. Mechanisms of resistance to topoisomerase inhibitors. In "Anticancer Drug Resistance, Advances in Molecular and Clinical Research," ed. L. J. Goldstein and R. F. Ozols, pp. 263-281 (1995). Kluwer Academic Publishers, Norwell.
13. Rubin, E., Pantazis, P., Bharti, A., Toppmeyer, D., Giovanella, B. and Kufe, D. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitrocamptothecin. J. Biol. Chem., 269, 2433-2439 (1994).
14. Benedictti, P., Fiorani, P., Capuani, L. and Wang, J. C. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cystine. Cancer Res., 53, 4343-4348 (1993).
15. Tamura, H., Kohchi, C., Yamada, R., Ikeda, T. and Koiwai, O. Molecular cloning of a cDNA of a campto- thecine-resistant human DNA topoisomerase I and identi- fication of mutation sites. Nucleic Acids Res., 19, 69-75 (1990).
16. Fujimori, A., Harker, W. G., Kohlhagen, G., Hoki, Y. and Pommier, Y. Mutation at the catalytic site of topoisomer- ase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res., 55, 1339-1346 (1995).
17. Kubota, N., Ohmori, T., Fujiwara, Y., Terashima, Y. and Saijo, N. Detection of topoisomerase I gene point muta- tion in CPT-11 resistant lung cancer cell line. Biochem. Biophys. Res. Commun., 188, 571-577 (1992).
18. Chomczynski, P. and Sacchi, N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol- chloroform extraction. Anal. Biochem., 162, 156-159 (1987).
19. D'Arpa, P., Machlin, P. S., Ratrie, III, H., Rothfield, N. F., Cleveland, D. W. and Earnshaw, W. C. cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxy-terminal fragment. Proc. Natl. Acad. Sci. USA, 85, 2543-2547 (1988).
20. Mohabeer, A. J., Hiti, A. L. and Martin, W. J. Non- radioactive single strand conformation polymorphism (SSCP) using the Pharmacia 'PhastSystem.' Nucleic Acids Res., 19, 3154 (1991).
21. Langemeier, J. L., Cook, R. F., Issel, C. J. and Montelaro, R. C. Comparative sensitivity of alternative single-strand conformation polymorphism (SSCP) methods. BioTechniques, 17, 490-496 (1994).
22. Bender, T. P. Identification of newly transcribed RNA. In "Current Protocols in Molecular Biology, Vol. 1, Unit 4. 10. IF," ed. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith and K. Struhl (1993). John Wiley & Sons, Inc., New York.
23. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-685 (1970).
24. Hasegawa, T., Isobe, K., Nakashima, I. and Shimokata, K. Higher expression of topoisomerase II in lung cancers than normal lung tissues: different expression pattern from topoisomerase I. Biochem. Biophys. Res. Commun., 195, 409-414 (1993).
25. Ohashi, N., Fujiwara, Y., Isobe, T., Sumiyoshi, H., Murakami, I., Okusaki, K., Niitani, K., Egusa, Y., Yamaoka, N., Yamakido, M., Katoh, O., Kimura, A. and Satow, Y. Topoisomerase I gene alteration in tumor samples from lung cancer patients. Proc. Am. Assoc. Cancer Res., 36, 640 (1995).
26. Kubo, A., Yoshikawa, A., Hirashima, T., Masuda, N., Takada, M., Takahara, J., Fukuoka, M. and Nakagawa, K. Point mutations of the topoisomerase lia gene in patients with small cell lung cancer treated with etoposide. Cancer Res., 56, 1232-1236 (1996).
27. Mcleod, H. L., Douglas, F., Oates, M., Symonds, R. P., Prakash, D., van der Zee, A. G. J., Kaye, S. B., Brown, R. and Keith, W. N. Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int. J. Cancer, 59, 607-611 (1994).
28. Goldwasser, F., Bae, I., Valenti, M., Torres, K. and Pommier, Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res., 55, 2116-2121 (1995).
29. Sugimoto, Y., Tsukahara, S., Oh-hara, T., Isoe, T. and Tsuruo, T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res., 50, 6925-6930 (1990).
30. Takeda, S., Shimazoe, T., Sato, Y. K., Sugimoto, Y., Tsuruo, T. and Kono, A. Differential expression of DNA topoisomerase I gene between CPT-11 acquired- and native-resistant human pancreatic tumor cell lines: de- tected by RNA/PCR-based quantitation assay. Biochem. Biophys. Res. Commun., 184, 618-625 (1992).
31. Husain, I., Mohler, J. L., Seigler, H. F. and Besterman, J. M. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demon- stration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res., 54, 539-546 (1994).